Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics

Abstract

The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

1 . An isolated nucleic acid selected from the group consisting of:
 (a) a nucleic acid encoding a fragment of the polypeptide of SEQ ID NO.: 3850;   (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);   (c) a complement of (a) or (b);   (d) an RNA of (a), (b), or (c), wherein U is substituted for T; and,   (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d).   
     
     
         2 . A recombinant expression vector comprising the nucleic acid of  claim 1  operably linked to a transcription regulatory element. 
     
     
         3 . A cell comprising a recombinant expression vector of  claim 2 . 
     
     
         4 . An isolated nucleic acid selected from the group consisting of:
 (a) a nucleic acid encoding 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.: 3850;   (b) a nucleic acid having 90% identity to the nucleic acid of (a);   (c) a complement of (a) or (b);   (d) an RNA of (a), (b), or (c), wherein U is substituted for T; and,   (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d).   
     
     
         5 . A recombinant expression vector comprising the nucleic acid of  claim 4  operably linked to a transcription regulatory element. 
     
     
         6 . A cell comprising a recombinant expression vector of  claim 5 . 
     
     
         7 . An isolated nucleic acid selected from the group consisting of:
 (a) a nucleic acid encoding about 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850;   (b) a nucleic acid having 90% identity to the nucleic acid of (a);   (c) a complement of (a) or (b);   (d) an RNA of (a), (b), or (c), wherein U is substituted for T; and,   (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d).   
     
     
         8 . A recombinant expression vector comprising the nucleic acid of  claim 7  operably linked to a transcription regulatory element. 
     
     
         9 . A cell comprising a recombinant expression vector of  claim 8 . 
     
     
         10 . An isolated nucleic acid selected from the group consisting of:
 (a) a nucleic acid comprising coding sequence for Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;   (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);   (c) a complement of (a) or (b);   (d) an RNA of (a), (b), or (c), wherein U is substituted for T; and,   (e) a nucleotide sequence hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d).   
     
     
         11 . A recombinant expression vector comprising the nucleic acid of  claim 10  operably linked to a transcription regulatory element. 
     
     
         12 . A cell comprising a recombinant expression vector of  claim 11 . 
     
     
         13 . An isolated nucleic acid selected from the group consisting of:
 (a) a nucleic acid encoding a fragment of the polypeptide of SEQ ID NO.: 3850;   (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);   (c) a complement of (a) or (b);   (d) an RNA of (a), (b), or (c), wherein U is substituted for T; and,   (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d);   and further comprising a nucleic acid encoding an amino acid sequence unrelated to the polypeptide shown in SEQ ID NO.:3850.   
     
     
         14 . A recombinant expression vector comprising the nucleic acid of  claim 13  operably linked to a transcription regulatory element. 
     
     
         15 . A cell comprising a recombinant expression vector of  claim 14 . 
     
     
         16 . An isolated nucleic acid selected from the group consisting of:
 (a) a nucleic acid encoding 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.: 3850;   (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);   (c) a complement of (a) or (b);   (d) an RNA of (a), (b), or (c), wherein U is substituted for T; and,   (f) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d);   and further comprising a nucleic acid encoding an amino acid sequence unrelated to the polypeptide shown in SEQ ID NO.:3850.   
     
     
         17 . A recombinant expression vector comprising the nucleic acid of  claim 16  operably linked to a transcription regulatory element. 
     
     
         18 . A cell comprising a recombinant expression vector of  claim 17 . 
     
     
         19 . An isolated nucleic acid selected from the group consisting of:
 (a) a nucleic acid encoding about 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850;   (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);   (c) a complement of (a) or (b);   (d) an RNA of (a), (b), or (c), wherein U is substituted for T; and,   (e) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d);   and further comprising a nucleic acid encoding an amino acid sequence unrelated to the polypeptide shown in SEQ ID NO.:3850.   
     
     
         20 . A recombinant expression vector comprising the nucleic acid of  claim 19  operably linked to a transcription regulatory element. 
     
     
         21 . A cell comprising a recombinant expression vector of  claim 20 . 
     
     
         22 . An isolated nucleic acid selected from the group consisting of:
 (a) a nucleic acid comprising coding sequence for Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;   (b) a nucleotide sequence having 90% identity to the nucleic acid of (a);   (c) a complement of (a) or (b);   (d) an RNA of (a), (b), or (c), wherein U is substituted for T; and,   (f) a nucleic acid hybridizable under high stringency conditions to a nucleic acid of (a), (b), (c), or (d);   and further comprising a nucleic acid encoding an amino acid sequence unrelated to the polypeptide shown in SEQ ID NO.:3850.   
     
     
         23 . A recombinant expression vector comprising the nucleic acid of  claim 22  operably linked to a transcription regulatory element. 
     
     
         24 . A cell comprising a recombinant expression vector of  claim 23 . 
     
     
         25 . A polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850. 
     
     
         26 . A composition comprising a polypeptide of  claim 25  in a pharmaceutically acceptable carrier. 
     
     
         27 . The composition of  claim 26  further comprising an adjuvant. 
     
     
         28 . The composition of  claim 27  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         29 . A polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850. 
     
     
         30 . A composition comprising a polypeptide of  claim 29  in a pharmaceutically acceptable carrier. 
     
     
         31 . The composition of  claim 30  further comprising an adjuvant. 
     
     
         32 . The composition of  claim 31  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         33 . A polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850. 
     
     
         34 . A composition comprising a polypeptide of  claim 33  in a pharmaceutically acceptable carrier. 
     
     
         35 . The composition of  claim 34  further comprising an adjuvant. 
     
     
         36 . The composition of  claim 35  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         37 . A polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys. 
     
     
         38 . A composition comprising a polypeptide of  claim 37  in a pharmaceutically acceptable carrier. 
     
     
         39 . The composition of  claim 38  further comprising an adjuvant. 
     
     
         40 . The composition of  claim 39  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         41 . A polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys. 
     
     
         42 . A composition comprising a polypeptide of  claim 41  in a pharmaceutically acceptable carrier. 
     
     
         43 . The composition of  claim 42  further comprising an adjuvant. 
     
     
         44 . The composition of  claim 43  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         45 . A fusion protein consisting essentially of a first amino acid sequence corresponding to a fragment of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850. 
     
     
         46 . A composition comprising a polypeptide of  claim 45  in a pharmaceutically acceptable carrier. 
     
     
         47 . The composition of  claim 46  further comprising an adjuvant. 
     
     
         48 . The composition of  claim 47  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         49 . A fusion protein consisting essentially of a first amino acid sequence corresponding to 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850. 
     
     
         50 . A composition comprising a polypeptide of  claim 49  in a pharmaceutically acceptable carrier. 
     
     
         51 . The composition of  claim 50  further comprising an adjuvant. 
     
     
         52 . The composition of  claim 51  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         53 . A fusion protein consisting essentially of a first amino acid sequence corresponding to 5, 10, 20, 50, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850. 
     
     
         54 . A composition comprising a polypeptide of  claim 53  in a pharmaceutically acceptable carrier. 
     
     
         55 . The composition of  claim 54  further comprising an adjuvant. 
     
     
         56 . The composition of  claim 55  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         57 . A fusion protein consisting essentially of a first amino acid sequence comprising Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence. 
     
     
         58 . A composition comprising a polypeptide of  claim 57  in a pharmaceutically acceptable carrier. 
     
     
         59 . The composition of  claim 58  further comprising an adjuvant. 
     
     
         60 . The composition of  claim 59  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         61 . A fusion protein consisting essentially of a first amino acid sequence comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence. 
     
     
         62 . A composition comprising a polypeptide of  claim 61  in a pharmaceutically acceptable carrier. 
     
     
         63 . The composition of  claim 62  further comprising an adjuvant. 
     
     
         64 . The composition of  claim 63  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         65 . A vaccine comprising a polypeptide selected from the group consisting of:
 (a) a polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850;   (b) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850;   (c) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850;   (d) a polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys; and,   (e) a polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;   and a pharmaceutically acceptable carrier.   
     
     
         66 . The vaccine of  claim 65  further comprising an adjuvant. 
     
     
         67 . The composition of  claim 66  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         68 . A vaccine selected from the group consisting of:
 (a) a fusion protein consisting essentially of a first amino acid sequence corresponding to a fragment of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (b) a fusion protein consisting essentially of a first amino acid sequence corresponding to 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (c) a fusion protein consisting essentially of a first amino acid sequence corresponding to 5, 10, 20, 50, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (d) a fusion protein consisting essentially of a first amino acid sequence comprising Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence; and,   (e) a fusion protein consisting essentially of a first amino acid sequence comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence;   and a pharmaceutically acceptable carrier.   
     
     
         69 . The vaccine of  claim 68  further comprising an adjuvant. 
     
     
         70 . The composition of  claim 69  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         71 . A method for treating or preventing infection by Steptococcus  pneumoniae  comprising administering to a host a composition comprising a polypeptide selected from the group consisting of:
 (a) a polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850;   (b) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850;   (c) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850;   (d) a polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys; and,   (e) a polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;   with a pharmaceutically acceptable carrier.   
     
     
         72 . The method of  claim 71  wherein the composition further comprises an adjuvant. 
     
     
         73 . The composition of  claim 72  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         74 . A method for treating or preventing infection by Steptococcus  pneumoniae  comprising administering to a host a composition comprising a polypeptide selected from the group consisting of:
 (a) a polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850;   (b) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850;   (c) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850;   (d) a polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys; and,   (e) a polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys;   with a pharmaceutically acceptable carrier.   
     
     
         75 . The method of  claim 71  wherein the composition further comprises an adjuvant. 
     
     
         76 . The composition of  claim 72  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         77 . A method for treating or preventing infection by Steptococcus  pneumoniae  comprising administering to a host a composition comprising a polypeptide selected from the group consisting of:
 (a) a fusion protein consisting essentially of a first amino acid sequence corresponding to a fragment of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (b) a fusion protein consisting essentially of a first amino acid sequence corresponding to 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (c) a fusion protein consisting essentially of a first amino acid sequence corresponding to 5, 10, 20, 50, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (d) a fusion protein consisting essentially of a first amino acid sequence comprising Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence; and,   (e) a fusion protein consisting essentially of a first amino acid sequence comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence;   with a pharmaceutically acceptable carrier.   
     
     
         78 . The method of  claim 77  wherein the composition further comprises an adjuvant. 
     
     
         79 . The composition of  claim 78  wherein the adjuvant is selected from the group consisting of aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine, RIBI, cholera toxin, a non-toxic derivatives of cholera toxin, the B subunit of cholera toxin, procholeragenoid, a fungal polysaccharide, schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of  E. coli , non- S. pneumoniae  bacterial lysates, block polymers, and saponins. 
     
     
         80 . An antibody that specifically binds to the polypeptide selected from the group consisting of:
 (a) a polypeptide comprising the amino acid sequence of a fragment of SEQ ID NO.:3850;   (b) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850;   (c) a polypeptide comprising 5, 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850;   (d) a polypeptide comprising the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys; and,   (e) a polypeptide comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys.   
     
     
         81 . An antibody of  claim 65  wherein the antibody is a monoclonal antibody. 
     
     
         82 . An antibody that specifically binds to the polypeptide selected from the group consisting of:
 (a) a fusion protein consisting essentially of a first amino acid sequence corresponding to a fragment of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (b) a fusion protein consisting essentially of a first amino acid sequence corresponding to 10, 20, 40, 50, 60, 100, or 150 contiguous amino acids of SEQ ID NO.:3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (c) a fusion protein consisting essentially of a first amino acid sequence corresponding to 5, 10, 20, 50, 100, or 150 contiguous amino acids from the C-terminus of SEQ ID NO.: 3850 and a second amino acid sequence unrelated to SEQ ID NO.:3850;   (d) a fusion protein consisting essentially of a first amino acid sequence comprising Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence; and,   (e) a fusion protein consisting essentially of a first amino acid sequence comprising a fragment of the amino acid sequence Pro Ile Ile Lys Ser Asn Ala Lys Glu Thr Leu Thr Gly Leu Lys Asn Asn Leu Leu Phe Gly Thr Gln Asp Asn Asn Thr Ile Met Ala Glu Ala Glu Lys Leu Leu Ala Leu Leu Lys Glu Ser Lys and a second amino acid sequence unrelated to the first amino acid sequence.   
     
     
         83 . An antibody of  claim 65  wherein the antibody is a monoclonal antibody.